# Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

> **NCT04505774** · PHASE4 · COMPLETED · sponsor: **Matthew Neal MD** · enrollment: 3591 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** theraputic heparin
- **DRUG:** prophylactic heparin
- **DRUG:** P2Y12
- **DRUG:** Crizanlizumab Injection
- **DRUG:** SGLT2 inhibitor

## Key facts

- **NCT ID:** NCT04505774
- **Lead sponsor:** Matthew Neal MD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-04
- **Primary completion:** 2023-08-31
- **Final completion:** 2024-01-26
- **Target enrollment:** 3591 (ACTUAL)
- **Last updated:** 2024-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04505774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04505774, "Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT04505774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*